Macrogenics Stock Discussion

$Macrogenics (MGNX.US)$ get up and let's go..

$Macrogenics (MGNX.US)$
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
MacroGenics (NASDAQ: MGNX) presented updated efficacy and safety results from the TAMARACK Phase 2 study of vobramitamab duocarmazine(vobra duo) for metastatic castration-resistant prostate cancer (mCRPC) at the ESMO Congress 2024.
Key findings include:
▪️6-month radiographic progression-free survival (rPFS) rate: 69% for 2.0 mg...

$Macrogenics (MGNX.US)$
MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
MacroGenics (NASDAQ: MGNX) announced a poster presentation of Phase 2 data for vobramitamab duocarmazine in metastatic castration-resistant prostate cancer (mCRPC) at the ESMO Congress 2024. The TAMARACK trial results will be presented on September 15, 2024, featuring updated safety and efficacy data, including the primary endpoint of 6-month radiographic progression-free survival (rPFS).
Th...

$Macrogenics (MGNX.US)$
f@#$%^&* up

$Macrogenics (MGNX.US)$ Under the 2017 collaboration agreement with Incyte, MacroGenics received an upfront payment of $150 million and has achieved a total of $215 million in milestones, including the recent $100 million described above. MacroGenics remains eligible to receive up to a total of $210 million in potential development and regulatory milestones and up to $330 million in potential commercial milestones. MacroGenics receives tiered royalties, w...

$Macrogenics (MGNX.US)$ Reuters· 1 min ago
MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration With Incyte

$Macrogenics (MGNX.US)$
MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte

$Macrogenics (MGNX.US)$ MacroGenics (MGNX) Investigating Three of Five Patient Deaths in TAMARACK Study of Vobra Duo, Stock Flat After May 10, 2024 Crash Hagens Berman Globe Newswire 10-Jul-2024 5:19 PM SAN FRANCISCO, July 10, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ:MGNX) investors who suffered substantial losses to submit your losses now. Visit: www.hbsslaw.com/investor-fraud/mgnx Contact t...

$Macrogenics (MGNX.US)$ being investigated for potential misleading of investigators with most recent clinical trial results in which 5 people died. Holding off entry till there's more clarity on that